Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Pokfulam, Hongkong
- GSK Investigational Site
-
Shatin, Hongkong
- GSK Investigational Site
-
-
-
-
-
Mexico, Mexiko, 6720
- GSK Investigational Site
-
Mexico city, Mexiko, 04530
- GSK Investigational Site
-
-
-
-
-
Taipei, Taiwan, 104
- GSK Investigational Site
-
Taipei, Taiwan
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10400
- GSK Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35244
- GSK Investigational Site
-
Birmingham, Alabama, Vereinigte Staaten, 35205
- GSK Investigational Site
-
Dothan, Alabama, Vereinigte Staaten, 36305
- GSK Investigational Site
-
-
Arkansas
-
Benton, Arkansas, Vereinigte Staaten, 72019
- GSK Investigational Site
-
Conway, Arkansas, Vereinigte Staaten, 72034
- GSK Investigational Site
-
Fayetteville, Arkansas, Vereinigte Staaten, 72703
- GSK Investigational Site
-
Jonesboro, Arkansas, Vereinigte Staaten, 72401
- GSK Investigational Site
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, Vereinigte Staaten, 92647
- GSK Investigational Site
-
Long Beach, California, Vereinigte Staaten, 90806
- GSK Investigational Site
-
Paramount, California, Vereinigte Staaten, 90723
- GSK Investigational Site
-
Sacramento, California, Vereinigte Staaten, 95816
- GSK Investigational Site
-
San Francisco, California, Vereinigte Staaten, 94102
- GSK Investigational Site
-
West Covina, California, Vereinigte Staaten, 91790
- GSK Investigational Site
-
-
Colorado
-
Longmont, Colorado, Vereinigte Staaten, 80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, Vereinigte Staaten, 06360
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, Vereinigte Staaten, 83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb, Illinois, Vereinigte Staaten, 60115
- GSK Investigational Site
-
-
Indiana
-
New Albany, Indiana, Vereinigte Staaten, 47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, Vereinigte Staaten, 67005
- GSK Investigational Site
-
Newton, Kansas, Vereinigte Staaten, 67114
- GSK Investigational Site
-
Wichita, Kansas, Vereinigte Staaten, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, Vereinigte Staaten, 40004
- GSK Investigational Site
-
Louisville, Kentucky, Vereinigte Staaten, 40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, Vereinigte Staaten, 71111
- GSK Investigational Site
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville, Michigan, Vereinigte Staaten, 49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul, Minnesota, Vereinigte Staaten, 55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68134
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Vereinigte Staaten, 89015
- GSK Investigational Site
-
-
New York
-
Cortland, New York, Vereinigte Staaten, 13045
- GSK Investigational Site
-
-
North Carolina
-
Boone, North Carolina, Vereinigte Staaten, 28607
- GSK Investigational Site
-
Cary, North Carolina, Vereinigte Staaten, 27518
- GSK Investigational Site
-
Raleigh, North Carolina, Vereinigte Staaten, 27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58103
- GSK Investigational Site
-
-
Ohio
-
Austintown, Ohio, Vereinigte Staaten, 44515
- GSK Investigational Site
-
Cincinnati, Ohio, Vereinigte Staaten, 45245
- GSK Investigational Site
-
Cleveland, Ohio, Vereinigte Staaten, 44121
- GSK Investigational Site
-
Dayton, Ohio, Vereinigte Staaten, 45406
- GSK Investigational Site
-
-
Oregon
-
Gresham, Oregon, Vereinigte Staaten, 97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Vereinigte Staaten, 16505
- GSK Investigational Site
-
Greenville, Pennsylvania, Vereinigte Staaten, 16125
- GSK Investigational Site
-
Latrobe, Pennsylvania, Vereinigte Staaten, 15650
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15236
- GSK Investigational Site
-
Uniontown, Pennsylvania, Vereinigte Staaten, 15401
- GSK Investigational Site
-
Wexford, Pennsylvania, Vereinigte Staaten, 15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville, Tennessee, Vereinigte Staaten, 37043
- GSK Investigational Site
-
Jackson, Tennessee, Vereinigte Staaten, 38305
- GSK Investigational Site
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78705
- GSK Investigational Site
-
Fort Worth, Texas, Vereinigte Staaten, 76135
- GSK Investigational Site
-
Houston, Texas, Vereinigte Staaten, 77055
- GSK Investigational Site
-
San Angelo, Texas, Vereinigte Staaten, 76904
- GSK Investigational Site
-
-
Utah
-
Bountiful, Utah, Vereinigte Staaten, 84010
- GSK Investigational Site
-
Layton, Utah, Vereinigte Staaten, 84041
- GSK Investigational Site
-
Murray, Utah, Vereinigte Staaten, 84107
- GSK Investigational Site
-
Provo, Utah, Vereinigte Staaten, 84604
- GSK Investigational Site
-
Roy, Utah, Vereinigte Staaten, 84067
- GSK Investigational Site
-
South Jordan, Utah, Vereinigte Staaten, 84095
- GSK Investigational Site
-
-
Virginia
-
Burke, Virginia, Vereinigte Staaten, 22015
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Experimental: Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Aktiver Komparator: Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Zeitfenster: Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Number of Subjects Who Seroconverted
Zeitfenster: Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Seroprotected Subjects
Zeitfenster: Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Seroconversion Factor
Zeitfenster: Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
|
Number of Subjects Reporting Solicited Local Symptoms
Zeitfenster: During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Solicited General Symptoms
Zeitfenster: During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Zeitfenster: During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Zeitfenster: During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
|
Number of Subjects Reporting Rare Serious Events
Zeitfenster: During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 111751
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Studiendaten/Dokumente
-
Datensatzspezifikation
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einwilligungserklärung
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistischer Analyseplan
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Kommentiertes Fallberichtsformular
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinischer Studienbericht
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einzelner Teilnehmerdatensatz
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Studienprotokoll
Informationskennung: 111751Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .